Voyxact (sibeprenlimab-szsi) is a new medicine approved by the FDA to lower protein levels in urine for adults with a kidney condition called primary immunoglobulin A nephropathy (IgAN) who are at risk of their illness… Read more

Itvisma (onasemnogene abeparvovec-brve) is a gene therapy that the FDA has approved to treat spinal muscular atrophy (SMA) in adults, teens, and children 2 or older who have a confirmed mutation in the survival motor… Read more

Hyrnuo (sevabertinib) is a new oral medicine for adults with advanced nonsquamous non-small-cell lung cancer (NSCLC) carrying a specific genetic change known as HER2 (ERBB2) TKD activating mutations and whose cancer has either advanced locally… Read more

The FDA has approved a new combination therapy that uses two different types of anticancer medicines for treating adults with muscle-invasive bladder cancer (MIBC) who can’t receive cisplatin, a common chemotherapy drug.The approved combination includes… Read more

Cavhanza (nilotinib) is a new FDA-approved orally disintegrating tablet (ODT) formulation of nilotinib, a prescription medicine used to treat a type of blood cancer called Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).The FDA has approved… Read more

Hympavzi (marstacimab‑hncq) is a preventive medicine you take as a once‑weekly shot under the skin.It is used in adults and in children 6 and older with hemophilia A or hemophilia B, whether or not you… Read more

Bemotrizinol is a sunscreen active ingredient that helps protect your skin from ultraviolet A (UVA) and ultraviolet B (UVB) rays.Parsol Shield is expected to be the first sunscreen available with this ingredient.The FDA has determined… Read more

Redemplo (plozasiran) is a type of medicine called a small interfering RNA (siRNA) therapy approved to help lower extremely high triglyceride levels in adults with familial chylomicronemia syndrome (FCS) or ongoing chylomicronemia.This medicine works by… Read more

Tzield (teplizumab-mzwv) is a prescription immune therapy that can help delay the progression of type 1 diabetes (T1D). The FDA has approved Tzield for slowing the decline of natural insulin production in children aged 8-17… Read more

Truqap (capivasertib) is an oral targeted cancer medicine. The FDA has now approved it to be used together with abiraterone and prednisone for a specific type of advanced prostate cancer. It applies to adults whose… Read more